PD-1与CTLA-4抑制剂联合姑息放疗耐受性的多中心评估
该多中心回顾性研究分析了133例接受CTLA-4或PD-1抑制剂联合放疗的转移性非小细胞肺癌、黑色素瘤或肾细胞癌患者的免疫相关不良事件(ir-AEs)。聚焦姑息放疗与免疫检查点抑制剂联合总体耐受良好,ir-AE可控,且与照射部位无关。
要点
- CTLA-4与PD-1抑制剂联合使用者任何级别ir-AE发生率为71%,高于单药者的29%(P=.0008)。
- 放疗在免疫治疗14天内进行者任何级别ir-AE发生率为39%,其他患者为23%(P=.06)。
- 多数毒性为轻度,未发现照射部位与特定ir-AE的关联。
核心结论
- 聚焦姑息放疗联合CTLA-4和/或PD-1抑制剂耐受良好,ir-AE可控,且似乎与照射部位无关。
研究设计与样本
- 多中心回顾性队列研究,纳入133例接受至少1周期CTLA-4或PD-1抑制剂并放疗的转移性非小细胞肺癌、黑色素瘤或肾细胞癌患者。
主要发现
- 同时使用CTLA-4和PD-1抑制剂者任何级别ir-AE发生率为71%,单药者为29%(P=.0008)。
- 放疗在免疫治疗14天内进行者任何级别ir-AE发生率为39%,其他患者为23%(P=.06)。
- 接受较高EQD2者任何级别ir-AE更常见(P=.01)。
- 未发现照射部位与特定ir-AE的关联。
关键数值与推荐
- ir-AE依据CTCAE v4.0定义。
- CTLA-4抑制剂单药28例,PD-1抑制剂单药88例,两类抑制剂联合17例(序贯13例,同步4例)。
临床怎么用
- 聚焦姑息放疗联合CTLA-4和/或PD-1抑制剂可用于需要姑息放疗的免疫检查点治疗患者,ir-AE总体可控。
局限性
- 结论受患者和治疗异质性限制,需要未来验证性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze immune-related adverse events (ir-AEs) in patients treated with radiation and immune checkpoint blockade. METHODS AND MATERIALS: We retrospectively reviewed records from patients with metastatic non-small cell lung cancer, melanoma, or renal cell cancer who received at least 1 cycle of a CTLA-4 or PD-1 inhibitor and radiation. Immune-related adverse events, defined using Common Terminology Criteria for Adverse Events version 4.0, were tabulated in relation to treatment variables, and associations with sequencing and timing were assessed. RESULTS: We identified 133 patients, of whom 28 received a CTLA-4 inhibitor alone, 88 received a PD-1 inhibitor alone, and 17 received both classes of inhibitors either sequentially (n=13) or concurrently (n=4). Fifty-six patients received radiation within 14 days of an immune checkpoint inhibitor. Forty-six patients experienced at least 1 ir-AE (34.6%). Patients receiving both CTLA-4 and PD-1 inhibitors experienced more any-grade ir-AEs as compared with either individually (71% vs 29%, P=.0008). Any-grade ir-AEs occurred in 39% of patients in whom radiation was administered within 14 days of immunotherapy, compared with 23% of other patients (P=.06) and more often in patients who received higher equivalent dose in 2-Gy fractions (EQD2) EQD2 (P=.01). However, most toxicities were mild. There were no associations between site irradiated and specific ir-AEs. CONCLUSIONS: Our data suggest the combination of focal palliative radiation and CTLA-4 and/or PD-1 inhibitors is well tolerated, with manageable ir-AEs that did not seem to be associated with the particular site irradiated. Although conclusions are limited by the heterogeneity of patients and treatments, and future confirmatory studies are needed, this information can help guide clinical practice for patients receiving immune checkpoint therapy who require palliative radiation therapy.
引用
- Bang A, Wilhite TJ, Pike LRG, et al. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017. PMID: 28463153. doi:10.1016/j.ijrobp.2017.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。